Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2014-02-28Clinical Trial Update: Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder
A clinical trial update examining plasma orexin A levels and pre-pro-orexin mRNA expression in individuals with Attention-Deficit Hyperactiv…
-
CLINICAL_TRIALS withdrawal · 2014-02-26Clinical Trial Update: Effect of Methylphenidate on Connectivity [Phase 4]
Phase 4 trial evaluating methylphenidate on brain connectivity in attention-deficit/hyperactivity disorder has been withdrawn.
-
CLINICAL_TRIALS research · 2014-02-25Clinical Trial Update: The Effect of Non-pharmacological Novel Cognitive Interventions on Motor-Cognitive Function in Children With ADHD [NA]
A clinical trial investigating non-pharmacological cognitive interventions to improve motor-cognitive function in children with attention de…
-
FDA label_change · 2014-02-21FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for STRATTERA (atomoxetine hydrochloride) from Eli Lilly and Company. The action updates the product…
-
CLINICAL_TRIALS trial_result · 2014-02-21Clinical Trial Update: Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study [NA]
A completed pilot trial evaluated memantine for executive dysfunction in adults with ADHD. Results were posted in 2014.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-02-21Clinical Trial Update: An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 2]
Phase 2 open-study of Tipepidine Hibenzate in patients with attention-deficit/hyperactivity disorder has completed.
-
FDA approval · 2014-02-20FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for STRATTERA (atomoxetine hydrochloride) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2014-02-20Clinical Trial Update: Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity [Phase 4]
A Phase 4 study evaluating Vyvanse (lisdexamfetamine dimesylate) in children with ADHD and obesity was terminated, with results related to g…
-
FDA approval · 2014-02-19FDA Approved: GUANFACINE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application to authorize a generic guanfacine hydrochloride product from Amneal Pharmaceuticals of New York LLC.…
-
FDA approval · 2014-02-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for a generic combination of amphetamine salts (dextroamphetamine saccharate, amphetamine a…
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study [NA]
A completed clinical trial evaluating telemental health treatment for children with attention-deficit/hyperactivity disorder. The sponsor is…
-
FDA approval · 2014-02-07FDA Approved: RITALIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for RITALIN (methylphenidate hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2014-02-06Clinical Trial Update: A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms [Phase 3]
Phase 3 pilot trial update of Daytrana for children with autism co-morbid ADHD symptoms; results have been posted.
-
CLINICAL_TRIALS trial_result · 2014-02-06Clinical Trial Update: An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 4]
Phase 4 efficacy and safety study of osmotic-release methylphenidate in individuals with attention-deficit/hyperactivity disorder has comple…
-
CLINICAL_TRIALS trial_result · 2014-01-29Clinical Trial Update: Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder
This clinical trial update reports the completed study evaluating the validity of a genetic risk assessment tool to identify Autism Spectrum…
-
FDA approval · 2014-01-28FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for Dexmethylphenidate hydrochloride, a generic ADHD medication. This action confirms approval …
-
FDA approval · 2014-01-22FDA Approved: METHYLPHENIDATE HYDROCHLORIDE (LA) — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application for methylphenidate hydrochloride extended-release (LA) submitted by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2014-01-22FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for a generic dexmethylphenidate hydrochloride product from Amneal Pharmaceuticals, enabling continu…
-
FDA approval · 2014-01-22FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approves a supplemental ANDA for a combination of amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate monohydrate, de…
-
FDA approval · 2014-01-16FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' supplemental application for methylphenidate hydrochloride. The approval pertains to a labeling …
-
CLINICAL_TRIALS trial_result · 2014-01-14Clinical Trial Update: Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder [Phase 2]
Phase 2 trial comparing two doses of MG01CI to placebo in adults with ADHD (predominantly inattentive type) has completed.
-
CLINICAL_TRIALS trial_result · 2014-01-10Clinical Trial Update: Working Memory Training in Young ADHD Children [Phase 4]
This clinical trial update notes the completion of a Phase 4 study evaluating working memory training for young children with Attention-defi…
-
CLINICAL_TRIALS research · 2014-01-06Clinical Trial Update: Multidimensional Measurement of Psychopharmacological Treatment Response
This ClinicalTrials.gov update describes a completed trial (NCT01184235) examining multidimensional measurement of psychopharmacological tre…
-
CLINICAL_TRIALS trial_result · 2014-01-03Clinical Trial Update: The Serotonin Transporter in Attention Deficit Hyperactivity Disorder
A clinical trial conducted by the Medical University of Vienna evaluating the serotonin transporter in Attention Deficit Hyperactivity Disor…
-
FDA approval · 2013-12-31FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma, LLC)
The FDA approved a supplemental application for Epic Pharma's generic combination of amphetamine salts (dextroamphetamine saccharate, amphet…